MedTrace Logo

Blood Lactate Level for Pre-hospital Orientation of Septic Shock

NCT03831685 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2019-02-11

No results posted yet for this study

Summary

In the pre-hospital setting, the severity assessment of septic shock is essential to decide the optimal initial in-hospital level of care. As clinical signs can be faulted, there is a need for an additional element in order to enhance the severity assessment and to decide in-hospital admission in the intensive care unit (ICU) or in the emergency department (ED). Point of care medical device yielding blood lactate levels since the pre-hospital setting may give an easy and valuable element for the severity assessment and the decision-making.

The aim of this study is to provide clinical evidence that the pre-hospital blood lactate level predicts the 30-day mortality of patients with septic shock.

Conditions

  • Sepsis
  • Lactate Blood Increase

Interventions

OTHER

Blood sample

Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.

Sponsors & Collaborators

  • Fire Brigade Of Paris Emergency Medicine Dept

    collaborator OTHER

  • University Hospital, Grenoble

    collaborator OTHER

  • University Hospital, Toulouse

    collaborator OTHER

  • University Hospital Center of Martinique

    collaborator OTHER

  • Hôpital Necker-Enfants Malades

    lead OTHER

Principal Investigators

  • Romain Jouffroy, MD · APHP - Necker enfants malades Hospital - SAMU Anesthesiology and intensive care unit

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03831685 on ClinicalTrials.gov